Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,471Revenue (TTM) $M695Net Margin (%)-36.9Altman Z-Score9.9
Enterprise Value $M8,207EPS (TTM) $-1.7Operating Margin %-36.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-37.8Higher ROA y-yN
Price/Book7.010-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsY
Price/Sales12.15-y EBITDA Growth Rate %--Current Ratio4.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-14.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-20.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M152ROIC % (ttm)-24.9Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSKen Fisher 2016-12-31 Reduce$42.3 - $59.5
($53.46)
$ 55.744%Reduce -8.64%118,407
ALKSGeorge Soros 2016-09-30 Buy 0.01%$43.77 - $51.78
($47.55)
$ 55.7417%New holding4,600
ALKSKen Fisher 2016-09-30 Add$43.77 - $51.78
($47.55)
$ 55.7417%Add 5.29%129,607
ALKSKen Fisher 2016-06-30 Add$34.19 - $47
($41.15)
$ 55.7435%Add 2.33%123,094
ALKSVanguard Health Care Fund 2016-03-31 Add0.13%$29.05 - $79.38
($40.36)
$ 55.7438%Add 25.56%8,603,676
ALKSGeorge Soros 2016-03-31 Sold Out -0.01%$29.05 - $79.38
($40.36)
$ 55.7438%Sold Out0
ALKSKen Fisher 2016-03-31 Reduce$29.05 - $79.38
($40.36)
$ 55.7438%Reduce -0.02%120,297
ALKSGeorge Soros 2015-12-31 Reduce-0.01%$57.89 - $80.14
($70.39)
$ 55.74-21%Reduce -56.96%3,400
ALKSVanguard Health Care Fund 2015-12-31 Reduce$57.89 - $80.14
($70.39)
$ 55.74-21%Reduce -0.40%6,851,996
ALKSKen Fisher 2015-12-31 Add$57.89 - $80.14
($70.19)
$ 55.74-21%Add 0.34%120,327
ALKSVanguard Health Care Fund 2015-09-30 Add0.08%$55.08 - $72.79
($66.01)
$ 55.74-16%Add 10.43%6,879,583
ALKSGeorge Soros 2015-09-30 Buy 0.01%$55.08 - $72.79
($66.01)
$ 55.74-16%New holding7,900
ALKSKen Fisher 2015-09-30 Add$55.08 - $72.79
($66.01)
$ 55.74-16%Add 11.90%119,920
ALKSVanguard Health Care Fund 2015-03-31 Add$58.24 - $73.64
($68.32)
$ 55.74-18%Add 0.05%6,229,583
ALKSVanguard Health Care Fund 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 55.749%Add 0.05%6,226,383
ALKSKen Fisher 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 55.749%Add 10.18%107,164
ALKSVanguard Health Care Fund 2014-09-30 Add0.01%$41.54 - $51.75
($44.82)
$ 55.7424%Add 1.42%6,223,083
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 55.7425%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 55.7421%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 55.7421%New holding55,309
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2017-01-17Sell11,983$54.322.61view
Cooke ShanePresident, Alkermes plc 2017-01-09Sell550$60.27-7.52view
Stejbach MarkSVP/Chief Comm Off, Alks Inc 2017-01-09Sell547$60.27-7.52view
Cooke ShanePresident, Alkermes plc 2017-01-06Sell9,450$60.06-7.19view
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc. 2017-01-06Sell10,000$59.44-6.22view
Stejbach MarkSVP/Chief Comm Off, Alks Inc 2017-01-06Sell9,453$60.05-7.18view
BREYER ROBERT ADirector 2017-01-04Sell4,000$60-7.1view
MITCHELL PAUL JDirector 2017-01-03Sell1,500$55.40.61view
Gaffin David JosephSVP, CLO, Alkermes, Inc. 2017-01-03Sell2,500$55.40.61view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2016-12-16Sell21,458$57.65-3.31view

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 

More From Other Websites
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017
Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More Jan 13 2017
Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal Jan 11 2017
Top Biotech Picks: "The Strong Will Survive And Thrive" Jan 05 2017
Alkermes Plc – Value Analysis (NASDAQ:ALKS) : January 5, 2017 Jan 05 2017
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017 Jan 04 2017
Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare... Jan 03 2017
Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare... Jan 03 2017
Alkermes’ Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare... Jan 03 2017
ETFs with exposure to Alkermes Plc : December 21, 2016 Dec 21 2016
Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock? Dec 08 2016
CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in... Dec 05 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 02 2016
CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to... Nov 30 2016
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare... Nov 18 2016
Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election Nov 15 2016
Drug pricing pressure Nov 15 2016
ETF’s with exposure to Alkermes Plc : November 10, 2016 Nov 10 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)